Journal
JOURNAL OF CHILD NEUROLOGY
Volume 34, Issue 5, Pages 284-294Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0883073819827407
Keywords
antiepileptic drugs; efficacy; epilepsy; pediatric; seizures
Categories
Funding
- Eisai Inc.
Ask authors/readers for more resources
Study 232, an open-label pilot study with an extension phase, evaluated the pharmacokinetics and preliminary safety/tolerability and efficacy of adjunctive perampanel oral suspension (<= 0.18 mg/kg/d) in epilepsy patients aged >= 2 to <12 years. Patients were grouped into cohorts 1 (aged >= 7 to <12 years) and 2 (aged >= 2 to <7 years). The Core Study included pretreatment (<= 2 weeks) and treatment phases (7-week titration; 4-week maintenance; 4-week follow-up [for those not entering the extension]). The extension phase consisted of 41-week maintenance and 4-week follow-up periods. Pharmacokinetic data were pooled with adolescent pharmacokinetic data from phase II/III studies. Population pharmacokinetic analysis showed that perampanel pharmacokinetics was independent of age, weight, or liver function, suggesting age- or weight-based dosing is not required and that the same dose can be given to adults and children to achieve exposures shown to be efficacious. Perampanel was well tolerated and efficacious for <= 52 weeks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available